-
July 4, 2025 Lupin Launches Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% in the United States
-
July 1, 2025 Lupin Receives Approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Gel
-
July 1, 2025 Lupin Carves Out LupinLife Consumer Healthcare
-
June 26, 2025 Lupin Launches Prucalopride Tablets in the United States
-
June 25, 2025 Lupin Receives Approval from U.S. FDA for Prucalopride Tablets
-
June 16, 2025 Lupin and Sino Universal Pharmaceuticals Sign License and Supply Agreement for Tiotropium DPI in China
-
June 9, 2025 Lupin Foundation Flags off Mobile Medical Van in Palghar to Strengthen Non-Communicable Disease Care
-
June 7, 2025 Lupin Receives Tentative Approval from U.S. FDA for Oxcarbazepine ER Tablets
-
May 26, 2025 Lupin Announces Presentation of Phase 1 Data on LNP7457 (PRMT5 inhibitor) at the American Society of Clinical Oncology – Annual Meeting 2025
In this section
Media Contacts
-
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications